A Phase 2 interventional study of fulvestrant and anastrozole in Metastatic Breast Cancer, sponsored by AstraZeneca. Completed at 41 sites in 9 countries. Open to female participants aged 45 Years to 100 Years. Per ClinicalTrials.gov, last updated 2019-09-06.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing fulvestrant in Breast Neoplasms — 13 open to participants now, 23 under way, 5 of them phase 3. Fulvestrant · Breast Neoplasms.
Among the 95 studies testing fulvestrant in Breast Neoplasms, this one is the 23rd largest by enrollment of the 94 interventional ones that give a count, is one of 5 that started in 2006, is one of 59 in phase 2, and was the 19th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →13 of the 95 studies testing fulvestrant in Breast Neoplasms are open now, in 7 countries. Recruiting first, the newest first:
Korea University Guro Hospital · Sites in Korea, Republic of
Ages 19–80 · Women only
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
University of California, Irvine · Sites in United States
Ages 18+
Prof. Wolfgang Janni · Sites in Germany, Switzerland
Ages 18+ · Women only
Royal Marsden NHS Foundation Trust · Sites in France, United Kingdom
Ages 18+
By country, each count listing its studies:
Fulvestrant: first FDA approval 2002 (FASLODEX), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 45 Years to 100 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, fulvestrant is the treatment under test here. Read study by study →
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 63 · Phase 3 21 · Phase 4 4
First in 1997; this study’s year is marked. 5 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 205 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 71 across the 94 interventional studies. Of the 55 that completed or were terminated, 34 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 95 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
198 studies in Breast Neoplasms by AstraZeneca: 20 open now, 50 under way, 24 of them phase 3. Of 144 finished, 32 (22%) have results posted.
Among the 198 studies in Breast Neoplasms by AstraZeneca, this one is the 51st largest by enrollment of the 125 interventional ones that give a count, is one of 9 that started in 2006, is one of 31 in phase 2, and was the 20th registered.
AstraZeneca’s Breast Neoplasms studies by the year they started, since 1996.
7 of the studies testing fulvestrant in Breast Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01953588Phase 3Alliance for Clinical Trials in OncologyFulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | 2027-04-01 |
| NCT07163481Hunan Cancer HospitalA Trial to Evaluate Sacituzumab Govitecan in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Metastatic Breast Cancer Progressed on CDK4/6 Inhibitors | 2026-12 |
| NCT05305924The Methodist Hospital Research InstituteFulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer | 2026-12-01 |
| NCT00585507Beth Israel Deaconess Medical CenterEfficacy and Safety of 500mg of Fulvestrant | 2027-03-15 |
| NCT05319873Jonsson Comprehensive Cancer CenterRibociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | 2027-04-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 95 studies testing fulvestrant in Breast Neoplasms, from their registry updates:
Among AstraZeneca’s 198 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the efficacy and tolerability of Faslodex (fulvestrant) with Arimidex (anastrozole) in postmenopausal women with hormone receptor positive advanced breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Fulvestrant
Drug: fulvestrant
Anastrozole
Drug: anastrozole
500 mg intramuscular injection
Also known as: Faslodex, ZD9238
1 mg oral tablet
Also known as: Arimidex, ZD1033
Clinical Benefit Rate
A Clinical Benefit (CB) responder is defined as a patient having a best overall response of either complete response (CR), partial response (PR) or stable disease (SD) for at least 24 weeks evaluated according to modified RECIST. The Clinical Benefit Rate is the percentage of patients with CB.
Time frame: From randomisation to data cut off (DCO) for primary analysis. The first and the last patients were enrolled on 6 Feb 2006 and 11 Jul 2007 respectively. The DCO for primary analysis was on 10th Jan 2008, 6 months after the last patient was enrolled.
Objective Response Rate
For each patient with measurable disease at baseline, the determination of the overall response for each visit was carried out using a SAS program per Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Complete Response (CR): Disappearance of all target lesion (TL) and non-target lesions (NTLs) and no new lesions. Partial Response (PR): At least a 30% decrease in the sum of longest diameter of TLs (compared to baseline), no progression of NTLs and no new lesions. Objective response rate is defined as percentage of patients with either CR or PR.
Time frame: From randomisation to data cut off (DCO) for primary analysis. The first and the last patients were enrolled on 6 Feb 2006 and 11 Jul 2007 respectively. The DCO for primary analysis was on 10th Jan 2008, 6 months after the last patient was enrolled.
Time to Progression
Time from randomization until earlier of disease progression or death. Progression was defined according to RECIST: a patient is determined to have progressed if they have progression of target lesions, clear progression of existing non-target lesions, or the appearance of one or more new lesions. Progression of target lesions is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum of LD recorded. Kaplan-Meier estimates of median for each treatment are reported.
Time frame: From randomisation to data cut off (DCO) for primary analysis. The first and the last patients were enrolled on 6 Feb 2006 and 11 Jul 2007 respectively. The DCO for primary analysis was on 10th Jan 2008, 6 months after the last patient was enrolled.
Time to Treatment Failure
Time from randomization to treatment discontinuation
Time frame: From randomisation to data cut off (DCO) for 75% treatment failure. The first and the last patients were enrolled on 6 Feb 2006 and 11 Jul 2007. The DCO for 75% treatment failure was on 26 Mar 2010, 32 months after the last patient was enrolled.
Time to Progression (Investigator Assessed)
Time from randomization to disease progression (investigator assessed) or death from any cause. Progression was defined by investigator opinion, as patients did not have formal RECIST visits in the follow-up period after the data cut off for the primary analysis of the study.
Time frame: From randomisation to data cut off (DCO) for 75% treatment failure. The first and the last patients were enrolled on 6 Feb 2006 and 11 Jul 2007. The DCO for 75% treatment failure was on 26 Mar 2010, 32 months after the last patient was enrolled.
Postmenopausal women presenting with advanced breast cancer who had either never received endocrine therapy for advanced disease or had not received endocrine therapy in the previous 12 months in the adjuvant setting were recruited between 6th Feb 2006 and 11th July 2007.
| Milestone | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| Started | 102 | 103 |
| Completed | 23 | 10 |
| Not completed | 79 | 93 |
| Withdrew: Death | 63 | 74 |
| Withdrew: Did not consent to os follow-up | 16 | 19 |
A Clinical Benefit (CB) responder is defined as a patient having a best overall response of either complete response (CR), partial response (PR) or stable disease (SD) for at least 24 weeks evaluated according to modified RECIST. The Clinical Benefit Rate is the percentage of patients with CB.
| Percentage of Participants | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| Clinical Benefit Rate | 72.5 | 67.0 |
For each patient with measurable disease at baseline, the determination of the overall response for each visit was carried out using a SAS program per Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Complete Response (CR): Disappearance of all target lesion (TL) and non-target lesions (NTLs) and no new lesions. Partial Response (PR): At least a 30% decrease in the sum of longest diameter of TLs (compared to baseline), no progression of NTLs and no new lesions. Objective response rate is defined as percentage of patients with either CR or PR.
| Percentage of Participants | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| Objective Response Rate | 36.0 | 35.5 |
Time from randomization until earlier of disease progression or death. Progression was defined according to RECIST: a patient is determined to have progressed if they have progression of target lesions, clear progression of existing non-target lesions, or the appearance of one or more new lesions. Progression of target lesions is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as references the smallest sum of LD recorded. Kaplan-Meier estimates of median for each treatment are reported.
| Day | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| Time to Progression | NA (173 to NA) | 381 (168 to NA) |
Time from randomization to treatment discontinuation
| Day | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| Time to Treatment Failure | 536 (166 to 1303) | 387 (169 to 838) |
Time from randomization to disease progression (investigator assessed) or death from any cause. Progression was defined by investigator opinion, as patients did not have formal RECIST visits in the follow-up period after the data cut off for the primary analysis of the study.
| Day | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| Time to Progression (Investigator Assessed) | 712 (173 to 1331) | 400 (168 to 908) |
Time from randomization to death (any cause)
| Month | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| Overall Survival | 54.1 (29.7 to NA) | 48.4 (28.6 to 78.5) |
Collected over Non-serious adverse events = randomisation upto the point of data cut off for the primary efficacy analysis. Serious adverse events = randomisation up to the point of data cut off for the 65% overall survival analysis.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fulvestrant 500 mg | 63/102 (61.8%) | 24/101 (23.8%) | 71/101 (70.3%) |
| Anastrozole 1 mg | 74/103 (71.8%) | 22/103 (21.4%) | 70/103 (68%) |
| Event | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 2/101 | 0/103 |
| CARDIAC FAILURECardiac disorders | 2/101 | 0/103 |
| DECREASED APPETITEMetabolism and nutrition disorders | 2/101 | 0/103 |
| DEHYDRATIONMetabolism and nutrition disorders | 2/101 | 0/103 |
| FEMUR FRACTUREInjury, poisoning and procedural complications | 1/101 | 2/103 |
| TRANSIENT ISCHAEMIC ATTACKNervous system disorders | 0/101 | 2/103 |
| DEATHGeneral disorders | 0/101 | 2/103 |
| ATRIAL FIBRILLATIONCardiac disorders | 1/101 | 1/103 |
| BRONCHITISInfections and infestations | 1/101 | 0/103 |
| CHRONIC OBSTRUCTIVE PULMONARY DISEASERespiratory, thoracic and mediastinal disorders | 1/101 | 0/103 |
| Event | Fulvestrant 500 mg | Anastrozole 1 mg |
|---|---|---|
| BONE PAINMusculoskeletal and connective tissue disorders | 14/101 | 10/103 |
| HOT FLUSHVascular disorders | 8/101 | 14/103 |
| HEADACHENervous system disorders | 4/101 | 13/103 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 10/101 | 8/103 |
| CONSTIPATIONGastrointestinal disorders | 10/101 | 5/103 |
| NAUSEAGastrointestinal disorders | 10/101 | 7/103 |
| MYALGIAMusculoskeletal and connective tissue disorders | 3/101 | 9/103 |
| VOMITINGGastrointestinal disorders | 8/101 | 3/103 |
| ASTHENIAGeneral disorders | 8/101 | 8/103 |
| COUGHRespiratory, thoracic and mediastinal disorders | 5/101 | 8/103 |
| Age, Continuous(Years) | Fulvestrant 500 mg | Anastrozole 1 mg | Total |
|---|---|---|---|
| Mean | 66.6 ± 9.0 | 67.6 ± 9.3 | 67.1 ± 9.1 |
| Sex: Female, Male(Participants) | Fulvestrant 500 mg | Anastrozole 1 mg | Total |
|---|---|---|---|
| Female | 102 | 103 | 205 |
| Male | 0 | 0 | 0 |
Ran from Feb 2006 to primary completion in Jan 2008, 23 months.
Results were first posted in Aug 2009, 1 year 7 months after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 23 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fulvestrant